129 related articles for article (PubMed ID: 17974153)
1. Flowcytometric immunophenotyping of peripheral-blood leukocytes in relation to immunopathology and cellular proliferation of pleural mesothelioma.
ElGendy AM; Abbas Helmy WH; Ezz-ElArab A
Egypt J Immunol; 2006; 13(1):87-98. PubMed ID: 17974153
[TBL] [Abstract][Full Text] [Related]
2. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma.
Meloni F; Morosini M; Solari N; Passadore I; Nascimbene C; Novo M; Ferrari M; Cosentino M; Marino F; Pozzi E; Fietta AM
Hum Immunol; 2006; 67(1-2):1-12. PubMed ID: 16698419
[TBL] [Abstract][Full Text] [Related]
3. Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid.
Scherpereel A; Grigoriu BD; Noppen M; Gey T; Chahine B; Baldacci S; Trauet J; Copin MC; Dessaint JP; Porte H; Labalette M
BMC Cancer; 2013 Jul; 13():324. PubMed ID: 23816056
[TBL] [Abstract][Full Text] [Related]
4. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses.
Hegmans JP; Hemmes A; Hammad H; Boon L; Hoogsteden HC; Lambrecht BN
Eur Respir J; 2006 Jun; 27(6):1086-95. PubMed ID: 16540497
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma.
Cornelissen R; Lievense LA; Robertus JL; Hendriks RW; Hoogsteden HC; Hegmans JP; Aerts JG
Lung Cancer; 2015 Jun; 88(3):332-7. PubMed ID: 25843042
[TBL] [Abstract][Full Text] [Related]
6. Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything?
Lucchi M; Picchi A; Alí G; Chella A; Guglielmi G; Cristaudo A; Fontanini G; Mussi A
Interact Cardiovasc Thorac Surg; 2010 Apr; 10(4):572-6. PubMed ID: 20053697
[TBL] [Abstract][Full Text] [Related]
7. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma.
Anraku M; Cunningham KS; Yun Z; Tsao MS; Zhang L; Keshavjee S; Johnston MR; de Perrot M
J Thorac Cardiovasc Surg; 2008 Apr; 135(4):823-9. PubMed ID: 18374762
[TBL] [Abstract][Full Text] [Related]
8. Understanding of the immunological heterogeneity of canine mammary carcinomas to provide immunophenotypic features of circulating leukocytes as clinically relevant prognostic biomarkers.
Estrela-Lima A; Araújo MS; da Costa-Neto JM; Ribeiro LG; Damasceno KA; D'Assis MJ; Martins-Filho OA; Teixeira-Carvalho A; Serakides R; Cassali GD
Breast Cancer Res Treat; 2012 Feb; 131(3):751-63. PubMed ID: 21448671
[TBL] [Abstract][Full Text] [Related]
9. Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas.
Johansson L; Lindén CJ
Chest; 1996 Jan; 109(1):109-14. PubMed ID: 8549169
[TBL] [Abstract][Full Text] [Related]
10. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
11. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.
Awad MM; Jones RE; Liu H; Lizotte PH; Ivanova EV; Kulkarni M; Herter-Sprie GS; Liao X; Santos AA; Bittinger MA; Keogh L; Koyama S; Almonte C; English JM; Barlow J; Richards WG; Barbie DA; Bass AJ; Rodig SJ; Hodi FS; Wucherpfennig KW; Jänne PA; Sholl LM; Hammerman PS; Wong KK; Bueno R
Cancer Immunol Res; 2016 Dec; 4(12):1038-1048. PubMed ID: 27856426
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric study of T-cell subsets in lymphocytic pleural effusions.
Khalil RY; Khalil MM
Cytometry; 1997 Aug; 30(4):204-5. PubMed ID: 9298840
[No Abstract] [Full Text] [Related]
14. [Immunophenotyping of peripheral blood lymphocytes from Chilean chronic chagasic patients by flow cytometry].
Sánchez G; Zulantay I; Gajardo M; Venegas J; Villanueva R; Pérez A; Liendo F; Apt W; Solari A
Rev Med Chil; 2002 Apr; 130(4):363-7. PubMed ID: 12090100
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells.
Ebstein F; Sapede C; Royer PJ; Marcq M; Ligeza-Poisson C; Barbieux I; Cellerin L; Dabouis G; Grégoire M
Am J Respir Crit Care Med; 2004 Jun; 169(12):1322-30. PubMed ID: 15070823
[TBL] [Abstract][Full Text] [Related]
16. Unusual CD3+, CD4+ large granular lymphocyte expansion associated with a solid tumor.
Claudepierre P; Bergamasco P; Delfau MH; Voisin MC; Farcet JP; Larget-Pied B; Chevalier X
J Rheumatol; 1998 Jul; 25(7):1434-6. PubMed ID: 9676781
[TBL] [Abstract][Full Text] [Related]
17. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection.
Yamada N; Oizumi S; Kikuchi E; Shinagawa N; Konishi-Sakakibara J; Ishimine A; Aoe K; Gemba K; Kishimoto T; Torigoe T; Nishimura M
Cancer Immunol Immunother; 2010 Oct; 59(10):1543-9. PubMed ID: 20567822
[TBL] [Abstract][Full Text] [Related]
18. Recognition of pleural mesothelioma by mucin-1(950-958)/human leukocyte antigen A*0201-specific CD8+ T-cells.
Roulois D; Vignard V; Gueugnon F; Labarrière N; Grégoire M; Fonteneau JF
Eur Respir J; 2011 Nov; 38(5):1117-26. PubMed ID: 21540305
[TBL] [Abstract][Full Text] [Related]
19. Lymphohistiocytoid mesothelioma. An often misdiagnosed variant of sarcomatoid malignant mesothelioma.
Khalidi HS; Medeiros LJ; Battifora H
Am J Clin Pathol; 2000 May; 113(5):649-54. PubMed ID: 10800396
[TBL] [Abstract][Full Text] [Related]
20. The role of tumor cells in the modification of T lymphocytes activity--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I.
Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
Folia Histochem Cytobiol; 2011; 49(4):579-92. PubMed ID: 22252752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
